Heart disease is a type of cardiovascular disease that affects the heart’s structure and function. Several different heart ...

As a player in the growing telehealth sector, Hims & Hers Health ($HIMS) has grown significantly, driving its stock up over ...

Yesterday, the FDA said that GLP1 products are no longer on the shortage list. How does this impact Hims & Hers? Hims & Hers was distributing semaglutide, a compounded product. However ...

Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.

Despite semaglutide being the active ingredient in Hims & Hers Health Inc’s (NYSE:HIMS) compounded GLP-1 product, a Truist analyst notes that the recent FDA commentary has reignited investor ...

Hims & Hers Health Q3 2024 revenue projected to surpass estimates by $5M-$10M. Truist consumer survey shows 10% use compounded GLP-1 medications, while 14% prefer branded options. Thursday, The ...

This allows Hims & Hers to offer a variety of services, including consultations and health-related products like prescription medications and skincare items. This flexible approach helps the ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our P/B Growth Investor model based on the published ...

Bloomberg / Contributor / Getty Images Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration (FDA) said Eli Lilly's popular weight-loss drugs are no longer on its list ...

Hims & Hers (NYSE:HIMS), the telehealth platform that offers compounded versions of weight loss drugs, dropped more than 10% on Thursday after the FDA confirmed that Eli Lilly's (LLY) GLP-1 ...

NEW YORK, Oct. 4, 2024 /PRNewswire/ -- Hims & Hers Health ... More assets are invested in products based on our indices than products based on indices from any other provider in the world.